Compare Gitlab Inc (GTLB) vs Hims and Hers Health Inc (HIMS) Price & Performance

GitLab trades at $31.50, down 4.49% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $759.25M in 2025, though net income remained negative at -$6.33M. Recent earnings beats and a strategic position in AI-driven DevSecOps, including a fourth consecutive Gartner Magic Quadrant leadership recognition (Business Wire, 2026-06-17), highlight growth potential despite profitability challenges.

The outlook balances strong revenue growth and market position against high valuation multiples and persistent losses. Analyst consensus targets $32.50, suggesting modest upside, but risks include execution on profitability and competitive pressures in the software sector. Cash flow trends show improvement projected for 2026, yet investor caution is warranted given the elevated P/E ratio of 521.22.

Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.

Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.